Sun Pharma
Sun Pharma's US generics business remains under pressure in FY26
Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition
 "Sun Pharma's US generics business remains under pressure in FY26")
Sun Pharma posts Q4 profit of ₹2,714 crore on strong specialty drug demand
India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales
 "Sun Pharma posts Q4 profit of ₹2,714 crore on strong specialty drug demand")
Q4 results: Sun Pharma, Eicher Motors, and Colgate among 187 on May 22
Q4FY26 company results: Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also to release their January-March earnings today
 "Q4 results: Sun Pharma, Eicher Motors, and Colgate among 187 on May 22")
Why pharma stocks are emerging as safe bet amid global market turmoil
The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk
 "Why pharma stocks are emerging as safe bet amid global market turmoil")
Organon deal impact: Sun Pharma surges 16% in 10 days, nears record high
Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.
Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks
The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.
Sun Pharma weighs multiple funding options for $12 billion Organon deal
The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt
 "Sun Pharma weighs multiple funding options for $12 billion Organon deal")
India’s biggest pharma deal: Sun Pharma to acquire US-based Organon in $11.75 billion deal
India’s largest drugmaker by market capitalisation, Sun Pharmaceutical Industries Ltd, is set to acquire US-based Organon & Co for an enterprise value of $11.75 billion in one of the largest overseas
 "India’s biggest pharma deal: Sun Pharma to acquire US-based Organon in $11.75 billion deal")
Analyst suggests 'Bull Spread' on Midcap Nifty, Sun Pharma; check strategy
Nandish Shah of HDFC Securities has shared Bull Spread' on strategy on Midcap Nifty and Sun Pharma
 "Analyst suggests 'Bull Spread' on Midcap Nifty, Sun Pharma; check strategy")
Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy
According to bankers, the Indian pharma major plans to raise around $10 billion from various sources, while the remaining will be funded through internal accruals
Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?
Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.
 "Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?")
Sun Pharma bets on Organon front-end to drive global growth, efficiencies
Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end
Best of BS Opinion: India's FTA with New Zealand shows agile deal-making
From India's FTA strategy and Sun Pharma's global ambitions to LPG shortages, West Asia risks and Asean ties, here are the key insights from today's Opinion page
 "Best of BS Opinion: India's FTA with New Zealand shows agile deal-making")
Scale and efficiency: Organon's acquisition will benefit Sun Pharma
Organon's portfolio includes over 70 products across women's health and biosimilars
Sun Pharma's $11.75 bn Organon bet: Global pharma leap or balance risk?
Sun Pharma's $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns
Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal
Combined entity to have revenue of $12.4 billion; enters biosimilars big league
 "Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal")
Lack of growth visibility at Organon could cap Sun Pharma's gains
Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential
 "Lack of growth visibility at Organon could cap Sun Pharma's gains")
Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details
Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent
Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why
Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal
April 26 (Reuters) - India's Sun Pharmaceutical Industries will uy Organon & Co in an all-cash deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.